We are live on ! Find out more
HLVX

HilleVax
HLVX

Delisted

HLVX was delisted on the 16th of September, 2025.

Back to rankings

51 hedge funds and large institutions have $400M invested in HilleVax in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more capital invested

Capital invested by funds: $254M → $400M (+$146M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 16

0.52% more ownership

Funds ownership: 69.47% → 70% (+0.52%)

11% less funds holding

Funds holding: 57 → 51 (-6)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
51
Holders Change
-6
Holders Change %
-10.53%
% of All Funds
0.88%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
7
Increased
18
Reduced
16
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$6.87M
2
Invesco
Invesco
Georgia
+$1.03M
3
State Street
State Street
Massachusetts
+$799K
4
DM
Deerfield Management
New York
+$513K
5
BlackRock
BlackRock
New York
+$507K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$12M
2
SB
Samsara BioCapital
California
-$2.22M
3
Two Sigma Investments
Two Sigma Investments
New York
-$1.59M
4
GCM
Ghisallo Capital Management
Massachusetts
-$656K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$462K
Name Holding Trade Value Shares
Change 		Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$167M +$6.87M +472,677 +5%
DM
2
Deerfield Management
New York
$45.3M +$513K +35,283 +1%
A
3
Abingworth
United Kingdom
$31.4M – – –
RCM
4
RA Capital Management
Massachusetts
$30.1M – – –
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$18.8M +$16M +1,100,000 New
BlackRock
6
BlackRock
New York
$13.2M +$507K +34,872 +5%
PA
7
Perceptive Advisors
New York
$13.1M – – –
SG
8
StepStone Group
California
$11.6M – – –
Franklin Resources
9
Franklin Resources
California
$11.5M +$7.55K +519 +0.1%
Vanguard Group
10
Vanguard Group
Pennsylvania
$10.8M +$275K +18,947 +3%
SB
11
Samsara BioCapital
California
$10.4M -$2.22M -152,515 -20%
QUSVM
12
Qiming U.S. Ventures Management
Washington
$9.55M – – –
BI
13
BVF Inc
California
$6.54M -$887 -61 -0%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.89M +$118K +8,082 +4%
State Street
15
State Street
Massachusetts
$3.75M +$799K +54,965 +33%
FAM
16
Fred Alger Management
New York
$1.84M – – –
Northern Trust
17
Northern Trust
Illinois
$1.77M -$16.9K -1,165 -1%
Morgan Stanley
18
Morgan Stanley
New York
$1.76M -$14.3K -986 -0.9%
Charles Schwab
19
Charles Schwab
California
$1.57M +$16.8K +1,157 +1%
Invesco
20
Invesco
Georgia
$1.22M +$1.03M +71,107 New
UOC
21
UBS O'Connor
Illinois
$1.04M -$436K -30,000 -33%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$710K +$145K +9,966 +32%
TD Asset Management
23
TD Asset Management
Ontario, Canada
$356K – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$350K -$1.59M -109,500 -84%
WP
25
Woodline Partners
California
$344K +$292K +20,108 New
1
2 3

HLVX Hedge Fund Activity: Q3 2022 in Review

51 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in HilleVax (HLVX) for Q3 2022, worth a combined $400M — up 58% from $254M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of HLVX and 7 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 18 added.

The largest buyer was Frazier Life Sciences Management, adding an estimated $6.87M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $12M sold.

  • 51 institutional investors held HilleVax (HLVX) as of Q3 2022, down from 57 in Q2 2022.
  • Funds reported $400M of HilleVax stock for Q3 2022, up 58% quarter-over-quarter.
  • 7 funds opened new HilleVax positions in Q3 2022 and 13 closed out, a net change of -6 holders.
  • The largest HilleVax buyer in Q3 2022 was Frazier Life Sciences Management, an estimated $6.87M added.
  • The largest HilleVax seller in Q3 2022 was T. Rowe Price Associates, an estimated $12M sold.

Based on aggregated 13F filings for Q3 2022.